KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Sales (2020 - 2025)

Historic Return on Sales for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 0.73%.

  • Royalty Pharma's Return on Sales fell 7000.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of 0.59% for FY2024, which is 1300.0% down from last year.
  • Per Royalty Pharma's latest filing, its Return on Sales stood at 0.73% for Q3 2025, which was down 7000.0% from 0.16% recorded in Q2 2025.
  • Royalty Pharma's Return on Sales' 5-year high stood at 1.45% during Q2 2021, with a 5-year trough of 1.08% in Q4 2022.
  • Its 5-year average for Return on Sales is 0.5%, with a median of 0.38% in 2022.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -11700bps in 2022, then skyrocketed by 22800bps in 2023.
  • Royalty Pharma's Return on Sales (Quarter) stood at 0.09% in 2021, then tumbled by -1257bps to 1.08% in 2022, then surged by 212bps to 1.2% in 2023, then plummeted by -53bps to 0.56% in 2024, then grew by 29bps to 0.73% in 2025.
  • Its Return on Sales stands at 0.73% for Q3 2025, versus 0.16% for Q2 2025 and 0.76% for Q1 2025.